Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage Files for US Stock Listing to Support Apoptosis Portfolio

publication date: Jun 24, 2024

Suzhou Ascentage Pharma filed to list its shares in the US. In 2019, the company completed a $53 million Hong Kong IPO at a market capitalization that approached $900 million. The company develops drugs that restore the normal process of cell death to treat cancers and other diseases. Two weeks ago, Ascentage signed a $1.3 billion deal ($100 million upfront) with Japan’s Takeda for a global option (ex-China) on its lead product, a third-generation BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia and other hematological cancers. The drug, olverembatinib, is already approved in China. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here